GE HealthCare Unveils AI-Driven Radiation Therapy Innovations at ESTRO 2025

At the ESTRO 2025 Congress in Vienna, GE HealthCare announced plans to expand its radiation oncology portfolio and introduced new AI-enabled solutions to advance cancer treatment. Central to the announcement was the debut of MR Contour DL™, an AI model designed to automate organ segmentation in radiation therapy planning, enabling more efficient, accurate, and consistent treatment.

The company also revealed its intent to integrate Spectronic Medical’s MRI Planner software into its offerings. This AI-powered tool converts standard MR images into synthetic CT images for MR-only radiotherapy workflows, streamlining treatment planning and enhancing precision.

In addition, GE HealthCare showcased an updated version of its Intelligent Radiation Therapy (iRT) solution. The new iRT incorporates MR-guided workflows and supports third-party AI applications, allowing for more complex and integrated treatment planning.

With rising cancer cases worldwide, GE HealthCare emphasized its commitment to improving early detection, planning accuracy, and care delivery through innovative medical technologies. These advancements aim to accelerate timelines from diagnosis to treatment and improve patient outcomes across the globe.

GE HealthCare Q1 2025 Earnings Summary

GE HealthCare delivered a solid first quarter in 2025 with both revenue and profit growth, despite tariff-related headwinds and lower free cash flow. Key results include:

- Revenue: $4.8 billion, up 3% year-over-year (4% organic growth)
- Adjusted EBIT: $715 million, up 5%; margin of 15.0% (up 30 basis points)
- Net income: $564 million, up from $374 million
- Diluted EPS: $1.23 (GAAP), up from $0.81; Adjusted EPS: $1.01, up 12%
- Free cash flow: $98 million, down from $274 million
- Book-to-bill ratio: 1.09, with record 10% organic order growth

Segment highlights:

- Imaging revenue rose 4% (5% organic), with EBIT margin improving to 9.3%
- Pharmaceutical Diagnostics revenue increased 6% (8% organic), with EBIT margin of 32.4%
- Advanced Visualization Solutions and Patient Care Solutions saw modest growth, with margin pressure in Patient Care

Strategic updates:

- GE HealthCare launched the new PET radiotracer Flyrcado and introduced new AI-enabled imaging systems
- Completed acquisition of Nihon Medi-Physics to expand radiopharmaceutical capabilities
- Board approved a $1 billion share repurchase program

Updated 2025 guidance (reflecting tariff impacts):

- Organic revenue growth: 2% to 3% (unchanged)
- Adjusted EPS: $3.90 to $4.10 (lowered from $4.61 to $4.75)
- Adjusted EBIT margin: 14.2% to 14.4% (down from prior guidance of 16.7% to 16.8%)
- Free cash flow: at least $1.2 billion (previously at least $1.75 billion)

GE HealthCare continues to focus on precision care, innovation, and global expansion, with particular strength in the U.S. market and growing demand for its advanced diagnostics and therapy solutions.

GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conferences.

Bank of America Securities Healthcare Conference in Las Vegas, NV – May 13, 2025 at 10:00 am CT / 11:00 am ET

Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL – June 10, 2025 at 9:00 am CT / 10:00 am ET

Webcasts of these events can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the dates and times listed above.

GE HealthCare will showcase its latest advancements in breast cancer detection and diagnostics at the 2025 Society of Breast Imaging Symposium, highlighting technologies aimed at improving accuracy and patient-centered care.

Key announcements include:

- The Pristina Via mammography system, which offers improved workflows, faster image processing, and low-dose imaging for patients. It enhances both technologist experience and patient comfort, with zero-click acquisition and rapid image cycles.

- GE HealthCare will distribute DeepHealth’s SmartMammo, an AI-powered solution for radiology workflows, now cleared for use in the U.S. It integrates with Pristina and provides features like real-time data rendering and automatic lesion detection, especially effective for dense breast tissue.

- The Invenia ABUS Premium, an FDA-approved breast ultrasound system, is designed to detect cancer in dense breast tissue. It includes AI tools to enhance image quality, scanning speed, and diagnostic confidence.

- SenoBright HD and SerenaBright, FDA-cleared solutions for contrast-enhanced mammography and guided biopsies, help detect lesions more clearly and conduct biopsies in familiar settings using existing mammography equipment.

The company emphasizes its commitment to improving breast cancer screening through a combination of hardware, AI, and streamlined workflows to enhance diagnostic speed, accuracy, and patient outcomes.

You can find more at GE HealthCare’s booth #407 during the event or by visiting their official site. Let me know if you'd like this shortened further or tailored for a specific purpose.

GE HealthCare (Nasdaq: GEHC) will announce its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025.

The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.

GE HealthCare and Cincinnati Children’s Launch Pediatric Imaging Innovation Hub

GE HealthCare and Cincinnati Children’s have launched the first pediatric Care Innovation Hub to drive advancements in medical imaging for children. The collaboration aims to create child-specific technologies in MRI, ultrasound, molecular imaging, and CT, addressing the unique challenges of pediatric care. The hub will foster joint development of imaging tools, including high-density MR coils, AI-enhanced ultrasound, and pediatric-optimized PET, SPECT, and CT workflows. The initiative is designed to improve diagnostic accuracy, patient comfort, and access to precision care for children globally.

GE HEALTHCARE UNVEILS REVOLUTION™ VIBE CT SYSTEM TO ADVANCE CARDIAC IMAGING WITH AI INTEGRATION

GE HealthCare introduced the Revolution™ Vibe CT system at the American College of Cardiology 2025 meeting. Designed to improve access to high-quality cardiac imaging, Revolution Vibe offers Unlimited One-Beat Cardiac imaging and incorporates AI-driven tools like TrueFidelity DL, SnapShot Freeze 2, ECG-less Cardiac, and Effortless Workflow.

The system aims to address the growing global burden of cardiovascular disease (CVD), the world’s leading cause of death, by enhancing diagnostic accuracy, reducing scan times, and improving patient comfort. Revolution Vibe is engineered to handle challenging cases, such as patients with atrial fibrillation, stents, or bypasses, which often complicate CT imaging.

Its AI-powered workflow simplifies scan preparation and automates patient positioning and protocol selection, potentially reducing exam time by up to 50% and improving operational efficiency. The system also enables broader facility access to advanced cardiac CT angiography (CCTA), helping providers improve care delivery while managing costs effectively.

GE HealthCare’s new system reflects its continued focus on enabling personalized, connected care through technological innovation and operational scalability in cardiac diagnostics.